This ETF Holds Stocks Insiders Want to Own

A notable 10.4% of the Vanguard Health Care ETF's (VHT) weighted underlying holdings have experienced insider buying within the last six months, with significant activity in Moderna Inc (MRNA) and Neogen Corp (NEOG). Specifically, Moderna saw purchases from two directors and officers, including CEO Stephane Bancel, while Neogen had insider buying from eleven directors and officers, suggesting a potentially positive outlook from those with the most insight into these companies; MRNA and NEOG comprise 0.14% and 0.02% of VHT, respectively.

Analysis

A significant 10.4% of the Vanguard Health Care ETF's (VHT) weighted underlying holdings have experienced insider buying over the past six months, a notable signal often interpreted as management confidence in future prospects. Within this group, Moderna Inc. (MRNA), which constitutes 0.14% of VHT, saw substantial purchases from two key insiders: Director Paul Sagan acquired 31,620 shares for approximately $1.0 million (at $31.76 per share), and CEO Stephane Bancel purchased 160,314 shares for about $5.0 million (at $31.22 per share). These transactions occurred at prices considerably above MRNA's last reported trade price of $26.93, suggesting insiders perceived value even at those higher levels. Similarly, Neogen Corp. (NEOG), accounting for 0.02% of VHT, demonstrated even broader insider conviction with eleven directors and officers recently filing Form 4s indicating share purchases. Notable acquisitions include CEO John Adent buying 23,035 shares and CFO David Naemura acquiring 14,800 shares, as part of numerous transactions occurring at prices ranging from $4.59 to $11.11 per share, compared to NEOG's last trade price of $6.21. This widespread pattern of insider accumulation, particularly in MRNA and NEOG which exhibit strong positive sentiment scores of 0.8 each, implies that company leadership may view their respective stocks as undervalued or anticipate favorable developments, despite their current small individual weightings within the broader VHT portfolio.

Key Decisions for Investors

• Investors should consider the substantial and broad insider buying at Moderna (MRNA) and Neogen (NEOG) as a positive signal for these individual companies, potentially warranting further due diligence for direct investment, especially given the C-suite level participation.
• For Vanguard Health Care ETF (VHT) holders, the observation that 10.4% of its weighted holdings have seen recent insider purchases provides a constructive signal regarding the underlying stock selection and potential undervaluation within a segment of its healthcare portfolio.